Boston-based firm adds expertise across life sciences, private equity, capital markets, employment and IP for new base in Toronto | 1yr

The scores of 28 countries remain unchanged in International Intellectual Property (IP) index from the US Chamber of Commerce | 1yr

Biggest development in European IP law for decades will see new court open on 1 June | 1yr

A firm that historically focuses on personal injury surpasses more established players in representing the most plaintiffs in patent litigation cases in the US | 1yr

Hagit Elul arrives hot on the heels of Orrick’s deal to merge with US litigation firm; Hughes Hubbard reshuffles leadership | 1yr

Top 100 US firm secures partners in Washington DC and Silicon Valley from specialist firms | 1yr

New arrivals land mostly in US giant’s newly-official Philadelphia base to bolster life sciences, healthcare private equity and white collar practices | 1yr

Arrival of Brown Rudnick's former IP team lead, Tom Meyers, and Zachary Hyde follows UK firm's take over last week of a Texas private client boutique | 1yr

Associates, paralegals and business professionals affected; cuts follow similar move at Cooley | 1yr

Paul Lucchese joins Trinity Life Sciences from EnterpriseDB following creation of 'strategic partnership' with Bain & Company that saw Bain take minority stake in Trinity | 1yr

Siang Chin joins biotech company co-founded by Nobel laureate as Mammoth’s former GC heads to Intuitive | 1yr

Arrival of West Coast-based quartet set to fill 'missing piece' in San Francisco giant's IP litigation portfolio | 2yrs

Law Over Borders guide will help businesses navigate international laws and guidelines at inflection point for technology | 2yrs

Advent’s Caldic and Wilbur-Ellis’s Connell to merge to create €3bn global life sciences and speciality chemicals business | 2yrs

Michael Nutter and Merritt Westcott join as partners in Chicago and Houston respectively | 2yrs

New office will be headed by Baker Botts’ former Austin IP head Kevin Meek | 2yrs

Life sciences specialist Matthew Ferry becomes the sixth partner to have moved over since the start of the year | 2yrs

Deal is valued at $4.1bn and gives BMS access to Turning Point Therapeutics' pipeline of cancer drugs | 2yrs